Physician profile
Patrick Cahill
NPI 1578884698
$1,833.69
in general payments reported to CMS, 2019-2025
9 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.55 · 2020: $11.51 · 2021: $45.40 · 2022: $295 · 2023: $536 · 2024: $465 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,544.84 | 2022-2025 | Biktarvy, Epclusa |
| Viiv Healthcare Company | $124.76 | 2022 | |
| Amag Pharmaceuticals, INC. | $35.68 | 2019 | |
| Exact Sciences Corporation | $32.52 | 2024 | Cologuard Collection Kit |
| Exeltis, USA INC. | $24.17 | 2021 | |
| Vertical Pharmaceuticals, LLC | $21.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.23 | 2021 | |
| Millicent US INC | $17.11 | 2025 | Femlyv, Intrarosa |
| Janssen Biotech, INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cahill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.